Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071510 · ClinicalTrials.gov registry record
Evaluation of the Atlas Genetics io® CTNG System
A clinical trial of Gonorrhea and Chlamydia Trachomatis, sponsored by Binx Health Limited.
- Completed
- Registry status
- 7,128
- Enrollment target
- 10
- Study locations
NCT03071510: Completed study of Gonorrhea and Chlamydia Trachomatis, sponsored by Binx Health Limited.
NCT03071510 is a study of Gonorrhea and Chlamydia Trachomatis that has completed, run by Binx Health Limited. The registered enrollment target is 7,128 participants, above the 733-participant average among 10 other Gonorrhea trials with a reported enrollment target (872% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03071510, a study of Gonorrhea and Chlamydia Trachomatis, has completed, sponsored by Binx Health Limited.
- COMPLETED
- Registry status
- 7,128 participants
- Enrollment target
- 10
- Study locations
Study Summary
Atlas Genetics io® system results are compared with those obtained from comparator devices.
Primary Outcome
The assessment of the diagnostic accuracy of the study device as compared to positive Composite Infected Status from comparator devices
Conditions Studied
Interventions
- DEVICE Atlas Genetics io® system
Study Locations (10)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Wake Forest Center for Reproductive Medicine - Greensboro
Alabama
- University of Alabama - Birmingham
California
- AIDS Healthcare Foundation - Los Angeles
Indiana
- Indiana University - Indianapolis
Louisiana
- Louisiana State University - New Orleans
Maryland
- Johns Hopkins University - Baltimore
Mississippi
- University of Mississippi - Jackson
Pennsylvania
- Planned Parenthood Southeastern Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,128 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2019-08-30 |
What the finished NCT03071510 record still lists
NCT03071510 is an observational study that tracks outcomes without assigning an intervention. Its 7,128 participants enrollment target places it among the larger protocols in the corpus, above the 733-participant average among 10 other Gonorrhea trials with a reported enrollment target (872% higher).
The record links to 2 conditions, with Gonorrhea appearing as the primary indexed condition, and to 1 intervention - of which Atlas Genetics io® system is the first listed.
NCT03071510 lists 10 locations in 9 states (North Carolina, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT03071510 about?
NCT03071510 is a clinical study titled "Evaluation of the Atlas Genetics io® CTNG System". Atlas Genetics io® system results are compared with those obtained from comparator devices.
What is the current status of trial NCT03071510?
This trial is currently completed. The enrollment target is 7,128 participants. The study started on 2017-05-18. Estimated completion is 2019-08-30.
What conditions does trial NCT03071510 study?
This clinical trial studies the following conditions: Gonorrhea, Chlamydia Trachomatis.
What interventions are being tested in trial NCT03071510?
The interventions under investigation include: Atlas Genetics io® system (DEVICE).
Who is sponsoring clinical trial NCT03071510?
This trial is sponsored by Binx Health Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03071510 being conducted?
This trial has 10 study locations across Alabama, California, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gonorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03071510's enrollment target sits among peer trials
7,128 1st of 10 higher than 10 of 10 other Gonorrhea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gonorrhea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effectiveness of Relationship Education for Reducing HIV Incidence Among SGM
RECRUITING · NA
-
Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision
RECRUITING · NA
-
Online HIV Prevention for Young Male Couples
COMPLETED · Phase 2
-
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
COMPLETED · Phase 2
-
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
COMPLETED · NA
-
Aztreonam for Pharyngeal Gonorrhea
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI